Reaction

Bone Density Abnormal reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,725 reports · 52 co-occurring drugs

As of the last recalculation, Bone Density Abnormal appears in 3,725 FAERS reports alongside 52 co-occurring drug terms. The strongest observed disproportionality signal is ROMOSOZUMAB-AQQG (PRR 216.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Romosozumab-Aqqg	462	216.9	224.6
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	277	185.6	191.5
Emtricitabine And Tenofovir Alafenamide	337	182.5	188.1
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	299	180.5	186.0
Emtricitabine And Tenofovir Disoproxil Fumarate	1,038	175.9	180.0
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	467	164.5	168.8
Tenofovir Disoproxil Fumarate	314	57.9	58.4
Denosumab	717	24.3	24.3
Methylprednisolone Acetate	33	23.2	23.3
Risedronate Sodium	60	10.9	11.0
Dolutegravir Sodium	16	9.9	10.0
Indomethacin	22	9.3	9.3
Sulfasalazine	125	9.2	9.2
Teriparatide	173	8.9	9.0
Raloxifene Hydrochloride	23	8.9	8.9
Diphenhydramine Hydrochloride Capsule, Liquid Filled	31	8.2	8.2
Leflunomide	145	8.0	8.0
Hydroxychloroquine Sulfate	126	8.0	8.0
Asfotase Alfa	14	7.8	7.8
Calcium	188	7.4	7.4
Meperidine Hydrochloride	11	6.7	6.7
Hydroxychloroquine	78	5.9	5.9
Magnesium Sulfate	13	5.6	5.6
Zoledronic Acid	39	5.5	5.5
Naproxen Sodium Tablet, Coated	13	5.4	5.4
Naproxen Sodium, Coated Tablets	13	5.4	5.4
Naproxen Sodium 220Mg	13	5.4	5.4
Magnesium Sulfate In Water For	12	5.3	5.3
Magnesium Sulfate Heptahydrate	12	5.2	5.2
Cyanocobalamin	29	5.0	5.0
Lopinavir And Ritonavir	11	4.5	4.5
Alendronate Sodium Tablet	14	4.2	4.2
Tofacitinib Citrate	9	3.8	3.8
Tofacitinib	118	3.7	3.7
Abatacept	87	3.6	3.6
Atazanavir	9	3.5	3.5
Abaloparatide	18	3.4	3.4
Raltegravir	10	3.4	3.4
Conjugated Estrogens	35	3.4	3.4
Anakinra	10	3.4	3.4
Darunavir	9	3.3	3.3
Estrogens, Conjugated	35	3.3	3.3
Estradiol	50	3.3	3.3
Icosapent Ethyl	4	2.6	2.6
Relugolix	10	2.4	2.4
Golimumab	34	2.2	2.2
Certolizumab Pegol	37	1.8	1.8
Diroximel Fumarate	3	1.4	1.4
Avapritinib	3	1.4	1.4
Buprenorphine	20	1.2	1.2
Alirocumab	5	1.1	1.1
Cinacalcet Hydrochloride	5	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.